PURPOSE: Inconsistency of reported associations between the C1420T polymorphism in the cytosolic serine hydroxymethyltransferase (SHMT1) gene and colorectal cancer (CRC) prompted us to undertake a meta-analysis. METHODS: We conducted searches of published literature in MEDLINE through PubMed up to April 2012. Individual data on 5,043 cases and 6,311 controls from 15 published case-control studies were evaluated. Meta-analyses were performed on the compiled dataset. RESULTS: In the overall analysis, association was lacking between the C1420T polymorphism and CRC risk (odds ratio [OR] 0.96-1.04, p = 0.47-0.77), materially unchanged when reanalyzed without the Hardy-Weinberg equilibrium-deviating studies (OR 1.03-1.09, p = 0.22-0.55) or subjected to outlier treatment (OR 0.89-0.99, p = 0.10-0.8). In the ethnic subgroups, Europeans were susceptible (OR 1.11-1.17, p = 0.13-0.48) and Americans, slightly protected (OR 0.86-0.87, p = 0.49-0.61). The increased risk effects, however, became null following outlier treatment (OR 0.95-1.06). Test for interaction between decreased risk associations in the low-folate subgroup (OR 0.60-0.85, p = 0.009-0.03) with the susceptible effects in the high-folate category (OR 1.14-1.22, p = 0.19-0.32) was significant (p interaction = 0.004). CONCLUSIONS: Overall summary estimates imply no associations but suggest geography-specific effects of the SHMT1 polymorphism that render Europeans susceptible, but not Americans. Folate status appears to show an inverse association of this polymorphism with CRC.
PURPOSE: Inconsistency of reported associations between the C1420T polymorphism in the cytosolic serine hydroxymethyltransferase (SHMT1) gene and colorectal cancer (CRC) prompted us to undertake a meta-analysis. METHODS: We conducted searches of published literature in MEDLINE through PubMed up to April 2012. Individual data on 5,043 cases and 6,311 controls from 15 published case-control studies were evaluated. Meta-analyses were performed on the compiled dataset. RESULTS: In the overall analysis, association was lacking between the C1420T polymorphism and CRC risk (odds ratio [OR] 0.96-1.04, p = 0.47-0.77), materially unchanged when reanalyzed without the Hardy-Weinberg equilibrium-deviating studies (OR 1.03-1.09, p = 0.22-0.55) or subjected to outlier treatment (OR 0.89-0.99, p = 0.10-0.8). In the ethnic subgroups, Europeans were susceptible (OR 1.11-1.17, p = 0.13-0.48) and Americans, slightly protected (OR 0.86-0.87, p = 0.49-0.61). The increased risk effects, however, became null following outlier treatment (OR 0.95-1.06). Test for interaction between decreased risk associations in the low-folate subgroup (OR 0.60-0.85, p = 0.009-0.03) with the susceptible effects in the high-folate category (OR 1.14-1.22, p = 0.19-0.32) was significant (p interaction = 0.004). CONCLUSIONS: Overall summary estimates imply no associations but suggest geography-specific effects of the SHMT1 polymorphism that render Europeans susceptible, but not Americans. Folate status appears to show an inverse association of this polymorphism with CRC.
Authors: Christine F Skibola; Martyn T Smith; Alan Hubbard; Barry Shane; Abby C Roberts; Graham R Law; Sara Rollinson; Eve Roman; Raymond A Cartwright; Gareth J Morgan Journal: Blood Date: 2002-05-15 Impact factor: 22.113
Authors: Maureen van den Donk; Brian Buijsse; Saskia W van den Berg; Marga C Ocké; Jan L Harryvan; Fokko M Nagengast; Frans J Kok; Ellen Kampman Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Simon M Collin; Chris Metcalfe; Luisa Zuccolo; Sarah J Lewis; Lina Chen; Angela Cox; Michael Davis; J Athene Lane; Jenny Donovan; George Davey Smith; David E Neal; Freddie C Hamdy; Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Kristrun R Benediktsdottir; Rosalind A Eeles; Michelle Guy; Zsofia Kote-Jarai; Jonathan Morrison; Ali Amin Al Olama; Kari Stefansson; Douglas F Easton; Richard M Martin Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08-25 Impact factor: 4.254
Authors: Tian Yang; Xue Li; Zahra Montazeri; Julian Little; Susan M Farrington; John P A Ioannidis; Malcolm G Dunlop; Harry Campbell; Maria Timofeeva; Evropi Theodoratou Journal: Int J Cancer Date: 2019-01-16 Impact factor: 7.396